About Hospital Guidance
exp date isn't null, but text field is
Produced by the Antimicrobial Management Group July 2020
Approved by Acute Drug and Therapeutics Committee
Review Date: July 2023
Summary of significant updates for July 2020 Guidance:
- Addition of oral switch guidance with preferred and alternate options for empirical IVOST for most scenarios
- Review of fluoroquinolone recommendations in guidance including link to MHRA statement
- Reduced IV antibiotic use, polypharmacy and need for therapeutic drug monitoring with increased use of levofloxacin where vancomycin and ciprofloxacin previously recommended
- Addition of alternative to gentamicin where significant nephrotoxicity concern
- Further scenarios covered in ENT section
- Ongoing rationalised use of “4C” antibiotics associated with higher risk of C.difficile infection